GlassScriptPhysician profile
Michael Ricardo
NPI 1336436229
$870.58
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.01 · 2020: $38.40 · 2021: $148 · 2022: $459 · 2023: $113 · 2024: $15.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $129.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $129.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $244.46 | 2019-2023 | |
| Pfizer INC. | $121.97 | 2021-2023 | |
| Coloplast Corp | $76.43 | 2022 | |
| Hologic Sales and Service, LLC | $68.62 | 2020-2022 | |
| Evofem Biosciences, INC. | $46.45 | 2022-2023 | Phexxi |
| Mayne Pharma Commercial LLC | $45.22 | 2021-2022 | |
| Exeltis, USA INC. | $43.90 | 2021-2024 | Slynd |
| Astellas Pharma US INC | $40.65 | 2022-2023 | Myrbetriq |
| Myovant Sciences INC. | $34.59 | 2022 | |
| Agile Therapeutics, INC. | $29.38 | 2021-2022 | |
| Exact Sciences Corporation | $16.99 | 2023 | Cologuard Collection Kit |
| Amag Pharmaceuticals, INC. | $14.98 | 2020 | |
| Organon LLC | $14.40 | 2022 | |
| Amgen INC. | $13.14 | 2021 | |
| Mylan Pharmaceuticals INC. | $12.22 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $12.20 | 2020 | |
| Avion Pharmaceuticals | $12.14 | 2021 | |
| Scynexis, INC. | $11.73 | 2022 | |
| Merck Sharp & Dohme LLC | $11.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Ricardo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.